Skip to content

Q-switched Neodymium-doped yttrium aluminium garnet (Nd:YAG) 532 nm nanosecond laser vs. Nd:YAG 532 nm picosecond laser for the treatment of solar lentigines in Asians

Q-switched Neodymium-doped yttrium aluminium garnet (Nd:YAG) 532 nm nanosecond laser vs. Nd:YAG 532 nm picosecond laser for the treatment of solar lentigines in Asians

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
TCTR
Registry ID
TCTR20171129001
Enrollment
30
Registered
2017-11-29
Start date
2017-10-09
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Solar lentigine 2 lesions on the arms solar lentigine picosecond laser

Interventions

1 lesion from each patient is randomized to the group treated with picosecond 532 nm laser. The lesion is treated only once at day 0. Energy selection depends on the endpoint of immediate whitening of
switched Nd:YAG 532 nm laser. The lesion is treated only once at day 0. Energy selection depends on the endpoint of immediate whitening of the lesions. Each patient is then followed up for results and
Experimental Device,Active Comparator Device
Picosecond 532 nm laser ,QS Nd YAG 532 nm laser

Sponsors

Division of Dermatology, Department of Internal Medicine, Faculty of Medicine Ramathibodi Hospital
Lead Sponsor
Mahidol University
Collaborator

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: -solar lentigines 2 lesions, at least 5 mm in diameter on the arms -able to comply with treatment regulations -able to attend every appointment assigned

Exclusion criteria

Exclusion criteria: -having photosensitive dermatoses -currently using photosensitizing agents -being pregnant or lactating woman -currently/previously having skin cancers -having a history of keloid/hypertrophic scars

Design outcomes

Primary

MeasureTime frame
Improvement score 6 and 10 weeks after last treatment Dermatologist evaluation using grading scale of 1 to 5, Luminance measured by using Chromameter CR-2

Secondary

MeasureTime frame
Side effects 6 and 10 weeks after treatment Assessed by dermatologists and patient's feedbacks (e.g. postinflammatory hyperpigmentation, postinf

Contacts

Public ContactWimolsiri Iamsumang

Division of Dermatology, Department of Internal Medicine, Faculty of Medicine Ramathibodi Hospital

wimolpahn@gmail.com662011166

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026